Disclaimer

Gilead Sciences, Inc., ("Gilead") maintains the Gilead Web site as a service to the Internet community. The Gilead Web site has been designed to provide general information about Gilead and its products. These pages are not intended to provide investment or medical advice, nor do they provide instruction on the appropriate use of products produced or supplied under development by Gilead, its affiliates, related companies, or its licensors or joint venture partners. Information on this Web site regarding products approved for marketing is qualified in its entirety by reference to the full prescribing information for products. Users of this Web site should be aware that products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials. Access and use of the Gilead Web site is subject to the terms and conditions set forth herein and all applicable laws, statutes, and/or regulations. Gilead may revise these terms and conditions from time to time without further notice by updating this posting.

Gilead will use reasonable efforts to include accurate and up-to-date information on the Gilead Web site, but Gilead makes no warranties or representations as to the accuracy of information presented on the Gilead Web site. In addition, any information presented on the Web site as of a particular date may only be accurate as of such date and Gilead disclaims any responsibility to update such information. Gilead shall not be held responsible for any action taken that is based on the information presented on the Gilead Web site, and all users of the Gilead Web site agree that all access and use of the Gilead Web site, and any and all content presented on the Gilead Web site, is at the user's own risk. Neither Gilead nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of user's access, use, or inability to use the Gilead Web site, or any errors or omissions in the content of the Gilead Web site. Any communication or material you transmit to Gilead via the Gilead Web site or Internet electronic mail is transmitted by you on a nonconfidential basis. Gilead makes no promise, express or implied, not to use such communication or material for any purpose whatsoever, including reproduction, publication, broadcast and posting.

It is the policy of Gilead to enforce its intellectual property rights to the fullest extent permitted under law. All product names, regardless of whether or not they appear in large print or with a trademark symbol, are trademarks of Gilead, its affiliates, related companies, or its licensors or joint venture partners, unless otherwise noted. The entire content of the Gilead Web site, including any images or text, is copyrighted and may not be distributed, downloaded, modified, reused, reposted, or otherwise used except as provided herein without the express written permission of Gilead. The use or misuse of these trademarks, copyrights, or other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, communications regulations and statutes, and other laws, statutes and/or regulations.

INDICATION: LETAIRIS is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening.

WARNING: POTENTIAL LIVER INJURY
LETAIRIS (ambrisentan) can cause elevation of liver aminotransferases (ALT and AST) to at least 3 times the upper limit of normal (ULN). LETAIRIS treatment was associated with aminotransferase elevations >3 x ULN in 0.8% of patients in 12-week trials and 2.8% of patients including long-term open-label trials out to one year. One case of aminotransferase elevations >3 x ULN has been accompanied by bilirubin elevations >2 x ULN. Because these changes are a marker for potentially serious liver injury, serum aminotransferase levels (and bilirubin if aminotransferase levels are elevated) must be measured prior to initiation of treatment and then monthly.

In the post-marketing period with another endothelin receptor antagonist (ERA), bosentan, rare cases of unexplained hepatic cirrhosis were reported after prolonged (>12 months) therapy. In at least one case with bosentan, a late presentation (after >20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by non-specific symptoms, all of which resolved slowly over time after discontinuation of the suspect drug. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment.

Elevations in aminotransferases require close attention. LETAIRIS should generally be avoided in patients with elevated aminotransferases (>3 x ULN) at baseline because monitoring liver injury may be more difficult. If liver aminotransferase elevations are accompanied by clinical symptoms of liver injury (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin >2 x ULN, treatment should be stopped. There is no experience with the re-introduction of LETAIRIS in these circumstances.

CONTRAINDICATION: PREGNANCY
LETAIRIS is very likely to produce serious birth defects if used by pregnant women, as this effect has been seen consistently when it is administered to animals [see Contraindications (4.1)]. Pregnancy must therefore be excluded before the initiation of treatment with LETAIRIS and prevented thereafter by the use of at least two reliable methods of contraception unless the patient has had a tubal sterilization or Copper T 380A IUD or LNg 20 IUD inserted, in which case no other contraception is needed. Obtain monthly pregnancy tests.

Because of the risks of liver injury and birth defects, LETAIRIS is available only through a special restricted distribution program called the LETAIRIS Education and Access Program (LEAP), by calling 1-866-664-LEAP (5327). Only prescribers and pharmacies registered with LEAP may prescribe and distribute LETAIRIS. In addition, LETAIRIS may be dispensed only to patients who are enrolled in and meet all conditions of LEAP [see WARNINGS, Prescribing and Distribution Program for LETAIRIS].

Please see full prescribing information, including important safety information and boxed WARNING.